The world saw the power of mRNA vaccines during the pandemic. Now, a startup in Hyderabad is taking the next leap, using artificial intelligence to create personalised vaccines that could one day teach our bodies to fight cancer.
The Promise of Personalised Medicine
For decades, the holy
grail of medicine has been personalisation: treatments designed not for the average person, but for you specifically. This is especially true in oncology. Cancer is not one disease; it is thousands of unique diseases, each driven by specific genetic mutations in a patient's tumour. A 'one-size-fits-all' approach often falls short. The concept of a personalised cancer vaccine is to analyse the unique genetic makeup of a patient’s tumour and create a treatment that trains their immune system to recognise and attack only the cancerous cells, leaving healthy tissue untouched. This is where messenger RNA, or mRNA, technology comes in. It provides a flexible platform to deliver a custom set of instructions to our cells.
From Blueprint to Vaccine: The AI Advantage
Creating a personalised vaccine is an immense challenge. First, scientists must sequence a patient's tumour to find its unique mutations. Then comes the hardest part: figuring out which of these mutations will produce abnormal proteins, known as neoantigens, that can trigger a powerful immune response. This is like searching for a handful of specific needles in a massive haystack of genetic data. This is where artificial intelligence becomes a game-changer. AI and machine learning algorithms can sift through vast amounts of genomic data at incredible speeds. They can predict which neoantigens are most likely to be effective, optimising the mRNA sequence for stability and ensuring it produces the right proteins once inside the body. This dramatically cuts down the time and cost of development.
Hyderabad's Biotech Innovator: PopVax
At the heart of this innovation in India is PopVax, a biotechnology startup based in Hyderabad. Founded by Soham Sankaran, the company is combining AI, machine learning, and molecular biology to pioneer these personalised cancer treatments. To accelerate this work, PopVax has launched the 'RNA Foundry,' an integrated facility for research, development, and manufacturing. This allows the entire process, from analysing a patient's tumour data to producing the experimental vaccine candidate, to happen under one roof. PopVax's platform analyses a patient's tumour sequencing data to identify the unique mutations and then uses its AI to design the mRNA vaccine. The company's work is not limited to cancer; it is also developing vaccines for infectious diseases and has a COVID-19 vaccine candidate in clinical trials.
The Road Ahead: Trials and Tribulations
While the technology is promising, it's important to note that these personalised cancer vaccines are still experimental. PopVax aims to manufacture over 100 personalised cancer vaccine candidates in the coming year, with each project taking roughly 8–10 weeks. The company has indicated plans to make these treatments available to a small number of patients through compassionate use and named–patient pathways by the end of 2026, pending regulatory approvals. A significant advantage of PopVax's technology is its stability; their vaccine platform is designed to be 'fridge–stable,' meaning it can be stored at regular refrigeration temperatures (2–8°C) for extended periods, a huge logistical advantage over first–generation mRNA vaccines that required ultra–cold storage. This could be crucial for deploying such advanced medicines in diverse settings.
